-
IWR-1-endo and the Next Era of Wnt Translation
2026-09-30
Translational Wnt research is moving beyond pathway description toward decision-quality evidence that connects mechanism, phenotype, and model context. This thought-leadership article examines how IWR-1-endo can serve as a practical Wnt signaling inhibitor within that framework, while drawing methodological lessons from high-content cardiomyopathy research.
-
Toremifene in Breast Cancer: 20 Years of Evidence
2026-09-29
This review synthesizes long-term clinical and pharmacologic evidence for toremifene as an endocrine option in hormone-sensitive breast cancer. Its main contribution is to place efficacy, metabolism, safety, bone and lipid effects, and treatment selection alongside tamoxifen and aromatase inhibitors rather than treating any single endpoint as decisive.
-
Indole-3-pyruvic acid: Bench Workflows
2026-09-29
Indole-3-pyruvic acid connects auxin biosynthesis, AhR-linked immune studies, and host–microbiome cancer research in one experimentally useful metabolite. This guide translates its biology into practical plant, PBMC, and tumor-model workflows with dose planning, controls, and troubleshooting guidance.
-
IPA Alleviates Rheumatoid Arthritis Through AhR Signaling
2026-09-28
The study links the tryptophan metabolite indole-3-pyruvic acid (IPA) to a more balanced Th17/Treg response and reduced disease severity in a rat model of rheumatoid arthritis. By combining patient metabolomics, peripheral immune-cell experiments, and collagen-induced arthritis studies, it provides preclinical evidence that AhR signaling contributes to IPA’s effects, while leaving human therapeutic efficacy untested.
-
Recombinant Mouse CD4: Practical Assay Workflows
2026-09-27
Use tag-free recombinant mouse CD4 to build controlled protein-binding and antibody-recognition assays, with practical steps for selecting controls and optimizing weak signals. The placental necroptosis study offers a useful example of pathway-level experimental design—but does not test CD4, so the article keeps those evidence streams distinct.
-
H-89 and Wnt-Driven Bone Anabolism
2026-09-26
Wnt-stimulated bone formation links PKA signaling to O-GlcNAcylation and glycolytic metabolism. Learn how H-89 can help translational researchers test this early signaling step—and why timing, orthogonal validation, and careful interpretation matter.
-
EZ Cap™ EGFP mRNA (5-moUTP) for Cell Assays
2026-09-26
A practical guide to using EZ Cap™ EGFP mRNA (5-moUTP), SKU R1016, as a reporter for separating mRNA delivery and translation from cell viability outcomes. It covers assay controls, interpretation, handling, and supplier-evaluation criteria while distinguishing product specifications from evidence generated with other delivery systems.
-
CTOP for μ-Opioid Receptor Signaling Research
2026-09-25
Use CTOP as a competitive pharmacological test of whether μ-opioid receptor activation contributes to a measured response—not as a substitute for circuit-specific evidence. The workflow connects receptor assays with mechanical pain research while emphasizing dose-finding, local-delivery controls, and careful interpretation of negative results.
-
7ACC2 and Tumor Metabolism: Flux Is Not Immunity
2026-09-25
7ACC2 is a potent monocarboxylate transporter 1 inhibitor for probing lactate handling in cancer models. This article explains how to separate transport effects from mitochondrial and macrophage immunometabolic biology—and how those distinctions shape stronger experiments.
-
Macrophage Models for Tumor Metabolic Immunology
2026-09-24
A mechanistic study in cholangiocarcinoma connects PDHA1 succinylation to α-ketoglutarate accumulation and impaired macrophage antigen presentation. This article translates that finding into practical guidance for designing macrophage experiments, interpreting M-CSF-supported models, and evaluating metabolic interventions without overstating clinical readiness.
-
Streptavidin – Cy5 for Apoptosis Assays
2026-09-24
Turn biotinylated antibodies or probes into far-red fluorescent readouts for microscopy and flow cytometry with Streptavidin – Cy5. Here’s how to apply it to USP42–JNK/p38 apoptosis experiments, with practical controls and starting conditions that should be optimized for each assay.
-
Claustrum Gene Expression Across Mammals
2026-09-23
This study proposes a cross-species framework for identifying conserved claustrum subdivisions by integrating gene expression, cytoarchitecture, and anatomical position. Its comparative in situ hybridization analysis provides a useful reference for interpreting claustrum organization across rodents, insectivores, tree shrews, and primates while clarifying the limits of direct mouse-to-primate translation.
-
Cl-Amidine: A Causal Map for PAD4 Studies
2026-09-22
Cl-Amidine trifluoroacetate salt enables controlled PAD4 perturbation while separating histone citrullination from AML transcriptional dependencies. This article develops an evidence-led assay strategy connecting PAD4 enzyme activity assay design with LMO2/LDB1 biology, cancer research, and inflammatory models.
-
EdU Imaging Kits (488) for PE-UCMSC Studies
2026-09-22
Discover how EdU Imaging Kits (488) can distinguish reduced S-phase entry from broader senescence phenotypes in preeclampsia-derived umbilical cord mesenchymal stem cells. This disease-focused framework combines click-chemistry labeling with microscopy, flow cytometry, and orthogonal validation for more defensible proliferation analysis.
-
(S)-(+)-Dimethindene maleate: Practical Guide
2026-09-21
This dossier-based guide explains how to use (S)-(+)-Dimethindene maleate as a research antagonist for experiments involving M2 muscarinic and histamine H1 receptor activity. It provides preparation, storage, assay-control, and troubleshooting guidance, while noting that the compound is not intended for diagnostic, therapeutic, or medical use and that directly matched paper evidence was not supplied.